Oncology · Clinical trials
Mesothelioma Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About mesothelioma — and why its trials are hard
Malignant mesothelioma is a rare, aggressive cancer of the mesothelial lining, most commonly the pleura, driven overwhelmingly by prior asbestos exposure and typically diagnosed at an advanced, unresectable stage after a long latency. For nearly two decades the systemic standard was cytotoxic chemotherapy: pemetrexed plus cisplatin, established by the pivotal Vogelzang/EMPHACIS trial, delivered a modest but real survival gain and became the backbone of first-line care. The major recent advance is dual immune checkpoint blockade: nivolumab plus ipilimumab (CheckMate-743) improved overall survival versus chemotherapy in unresectable pleural mesothelioma and is now a first-line standard, with especially pronounced benefit in non-epithelioid histology. Bevacizumab added to chemotherapy (MAPS trial) improved survival in France and is used in guidelines, though it is not FDA-approved for this indication. Beyond these, options are limited, multiple immunotherapy and targeted trials have failed, and prognosis remains poor. Multimodality management with surgery and radiation is reserved for selected early-stage patients, and effective second-line therapy remains a significant unmet need.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Nivolumab + Ipilimumab (Opdivo + Yervoy) | 2020 | First-line, unresectable malignant pleural mesothelioma | CheckMate-743 (phase 3) | Overall survival | Median OS 18.1 vs 14.1 mo, HR 0.74; greater benefit in non-epithelioid histology |
| Pemetrexed + Cisplatin (Alimta (pemetrexed)) | 2004 | First-line, unresectable malignant pleural mesothelioma | EMPHACIS / Vogelzang (phase 3) | Overall survival | Median OS 12.1 vs 9.3 mo vs cisplatin alone |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in mesothelioma development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Tremelimumab — DETERMINE (phase 2b, single-agent anti-CTLA-4) | Did not improve overall survival versus placebo in previously treated mesothelioma | CTLA-4 monotherapy insufficient; benefit later realized only in combination with anti-PD-1 |
| Bevacizumab — MAPS (phase 3, added to pemetrexed/cisplatin) | Improved OS in the trial but never gained FDA approval for mesothelioma | Regulatory/sponsor factors; benefit not translated into a US label despite positive data |
| Ranpirnase — Phase 3 (with doxorubicin) | Failed to significantly improve overall survival | Limited single-agent activity of the ribonuclease approach in a chemoresistant disease |
Choosing the right endpoint
Primary endpoints that matter in mesothelioma trials
- Overall survival (OS) — The primary and most meaningful endpoint anchoring both chemotherapy and immunotherapy approvals
- Progression-free survival (PFS) — Secondary measure; often less impressive than OS for immunotherapy in mesothelioma
- Overall response rate (ORR) — Supportive endpoint, though radiographic response is difficult to assess in rind-like pleural disease
- Histology (epithelioid vs non-epithelioid) — Key stratification/predictive factor; non-epithelioid tumors derive greater benefit from immunotherapy
- Disease control rate / lung function — Clinically relevant given symptom burden and the pleural encasement pattern of growth
How iNGENū runs mesothelioma trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Mesothelioma clinical trials — FAQs
What causes mesothelioma?
What is the current first-line treatment?
Why does mesothelioma remain hard to treat?
Ready to discuss your mesothelioma trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal